WHAT THE STUDY ACTUALLY SAYS

Omega-3 capsules moved blood pressure and inflammation markers in a small pilot

In 100 adults already treated for high blood pressure and high cholesterol, 12 weeks of 2 g/day omega-3 was linked to lower daytime and central blood pressure — but the authors call the signals exploratory.

Fish-oil capsules are among the most-taken supplements in the world, and the claim that they lower blood pressure and calm inflammation is a large part of why. A new randomised trial tested both effects at once, in a group where it matters most — people already on medication for high blood pressure and high cholesterol — and reported a cluster of favourable signals. The researchers are careful to say those signals are exploratory, not proof [s1].

What the trial did

The study was an exploratory, randomised, double-blind, placebo-controlled pilot trial [s1]. It enrolled 100 adults who were already receiving stable pharmacological treatment for hypertension and dyslipidaemia, and assigned them to either pharmaceutical-grade omega-3 ethyl esters at a capsule dose of 2 g/day or a matching placebo for 12 weeks, on top of their usual medication [s1].

The point of testing supplementation in already-treated patients is that it mirrors how omega-3 is actually used — as an add-on, not a replacement for drugs. The researchers measured inflammatory biomarkers, office and 24-hour ambulatory blood pressure, central (aortic) blood pressure, and vascular function, and estimated treatment effects with linear mixed-effects models [s1]. Two cautions are built into the analysis itself: the P values were nominal, and the 95% confidence intervals were not adjusted for the fact that many outcomes were tested at once [s1].

What it found

Compared with placebo, omega-3 supplementation was associated with a consistent set of reductions [s1]. The neutrophil-to-lymphocyte ratio, a general marker of inflammation, fell by 0.43 (95% confidence interval −0.73 to −0.13; P = 0.005), and ferritin by 47.32 ng/mL (95% CI −77.55 to −17.08; P = 0.003) [s1].

On blood pressure, daytime systolic pressure was lower by 6.52 mm Hg (95% CI −10.66 to −2.39; P = 0.002) and night-time diastolic pressure by 5.55 mm Hg (95% CI −9.87 to −1.22; P = 0.013) [s1]. Central systolic blood pressure — the pressure at the aorta, which tracks organ damage more closely than the reading at the arm — was lower by 6.71 mm Hg (95% CI −12.22 to −1.20; P = 0.019) [s1]. Estimated pulse-wave velocity, an algorithm-derived measure of arterial stiffness, was lower by 0.77 m/s (95% CI −1.19 to −0.36) [s1].

Taken at face value, that is a coherent picture: less inflammation, lower ambulatory and central pressure, and a stiffer-to-less-stiff shift in the arteries. The question is how much weight the picture can bear.

How to read it

Not much, yet — and the authors say so plainly. They describe the results as exploratory signals and state that multiplicity, the limited sample size, and incomplete outcome availability preclude a confirmatory interpretation [s1]. Each of those words is doing real work. "Multiplicity" means that when you test many outcomes without statistical correction, some will cross the significance line by chance, so a scatter of P values below 0.05 is weaker evidence than it looks. "Limited sample size" — 100 people split in two — means the effect estimates are imprecise, which the wide confidence intervals show directly. And a pilot trial is designed to decide whether a larger trial is worth running, not to settle the question itself.

There is also the matter of who was studied. These were patients already on blood-pressure and lipid medication, so the findings speak to omega-3 as an add-on in treated disease, not to a healthy person deciding whether to start fish oil [s1]. That makes the trial more relevant to clinical practice in one sense and less generalisable in another.

What to watch

The useful reading is that this trial does its job as a pilot: it identifies specific, measurable signals — the neutrophil-to-lymphocyte ratio, ferritin, selected ambulatory and central blood-pressure measures, and estimated pulse-wave velocity — that are worth testing properly [s1]. The authors call for independent replication in larger, prospectively registered trials with clearly specified endpoints and reproducible sample-size calculations [s1]. Until that arrives, the finding is a well-defined hypothesis, not a reason to change what anyone takes.

This article describes a single exploratory trial and is not medical or nutritional advice. Decisions about supplements alongside prescribed medication belong with a person's own clinician.

Sources

  1. Effects of Omega-3 Supplementation on Inflammatory Biomarkers and Ambulatory and Central Blood Pressure in Patients Treated for Hypertension and Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial — Nutrients , November 9, 2026

More on

Related coverage